Navigation Links
Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
Date:10/27/2008

CHENGDU, China, Oct. 27 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, November 11th, 2008. The Conference will be held on November 10th-12th at New York Palace Hotel in New York City.

The Company's presentation will take place in the Henry Salon (5th Floor) at 12:00 p.m. EST. Dr. Guoqing Jiang, Tianyin's Chairman and CEO, Mr. Allen Tang, assistant to the CEO, and Mr. Stewart Lor, a member of the Board of Directors, will be representing Tianyin at the conference and will be available for one-on-one meetings with analysts and investors throughout the day.

Management will discuss the Company's current product portfolio, development pipeline, research and development platform, recent financial highlights and its long term growth strategy.

Participation is by invitation and registration is mandatory. For more information on the conference contact your Rodman & Renshaw representative or visit http://www.rodmanandrenshaw.com.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 4 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufac
'/>"/>

SOURCE Tianyin Pharmaceutical (TPI)
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
2. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
5. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
6. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
7. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
8. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
9. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
10. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
11. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 In a ... industry suppliers will present technologies with applications in ... annual SPIE Optics and Photonics symposium ... SPIE, the international society for optics and ... multidisciplinary optical sciences and technology meeting in North ...
(Date:5/24/2013)... Toronto, Canada (PRWEB) May 24, 2013 ... selective barriers, and uptake or efflux transporters at the ... may be related to unbound fractions in the tissue ... understanding of these disposition challenges is required to guide ... and to identify any species-dependent variables that may impact ...
(Date:5/23/2013)... stopped breathing, his collapsed bronchus blocking the crucial flow ... watched helplessly, just praying that somehow the dire predictions ... had a good chance of not leaving the hospital ... Kaiba. "At that point, we were desperate. Anything that ... it." , They found hope at the University of ...
(Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... up to ... $385 million plus royalties -, PALO ALTO, ... announced today that it has entered into an agreement,granting exclusive ... countries to the Menarini Group. Menarini,with its significant pan-European presence, ...
... Management,Slate of InSite Vision, Including the Chairman and ... Sept. 11 PTV Sciences,("PTV"), a healthcare venture ... that RiskMetrics Group -(Formerly known as ISS), the ... that the,stockholders of InSite Vision Incorporated (Amex: ...
... 11 A project to advance,research and improve ... by a,new $1.6 million, three-year cooperative agreement with ... The agreement, intended to bring better care to ... National Fragile X Foundation (NFXF),the CDC,s National Center ...
Cached Biology Technology:CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 2CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 3CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 4CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 5RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 2RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 3RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 4$1.6 Million Agreement to Accelerate Fragile X Research, Inspire Hope 2
(Date:5/24/2013)... combat metastatic cancer , Cancer cells spread and ... system. Stimulation of the immune system can help to ... cause the immune system to ignore cancer cells. Regulatory ... the immune system response. In this issue of the ... Ronald Levy at Stanford University found that regulatory T ...
(Date:5/24/2013)... against Alzheimer,s disease, scientists have focused among other factors ... After all, it is the accumulation of A-beta that causes ... point for the formation of A-beta is APP. Alessia Soldano ... the function of APPL the fruit-fly version of APP ... Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ensures ...
(Date:5/23/2013)... National Laboratory honored more than 165 staff for ... at PNNL,s annual Intellectual Property Commercialization Recognition & ... Energy national laboratory named materials scientist Jun Liu ... battery materials that can store large amounts of ... reduce the time it takes to charge cell ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... , DNA-Prokids ( http://www.dna-prokids.org ), an international project ... victims and their relatives, was officially presented today, at the ... Traffic in human beings is one of the most ... century. According to data from the United Nations Office on ...
... rapid growth of institutional Memberships for open access ... of the "Online Reporting System" for its open ... BioMed Central,s cutting edge publishing platform, the new ... and help reduce the administrative costs associated with ...
... Stedim Biotech (SSB) and Adolf Kühner AG ,- Prototype ... ,Monthey, 19. Mai 2009 / b3c newswire ... to the biopharmaceutical industry, expands its product offering with ... OrbShake bioreactors rely on orbital shaking principles for ...
Cached Biology News:DNA-Prokids: Genetic identification against traffic in human beings 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 3
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
Request Info...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
... Maker, 1. Modular system for large ... up to six lab-cast or precast ... with 18- or 24-cm Immobiline DryStrip ... gel cassettes.Innovative design simplifies loading and ...
Biology Products: